🔗 Share this article

As the US undertakes historic revisions to its immunization recommendations, an unexpected name has emerged somewhat surprisingly: Dr. Tracy Beth Høeg, a US-based sports physician and public health researcher who rose to prominence by questioning COVID-19 shots in the pandemic and has zeroed in on potential fatalities after COVID-19 vaccination in her brief tenure at the Food and Drug Administration.

Proposed Shifts to Pediatric Vaccine Program

Health officials had intended to unveil radical changes to the childhood vaccination calendar recently, aligning the US with Denmark’s vaccine program, sources say – a significant shift that would put the US out of alignment with much of the international standard with little proof for public health gain. The announcement has been delayed until the coming year.

In place of the director of the vaccine center, Høeg is set to speak at the event. She was newly appointed acting director of the FDA’s drug evaluation center, the fifth individual to head the center this calendar year.

Consolidating Power at the Regulatory Body

Høeg's temporary position could signify a tighter collaboration between the pharmaceutical and vaccine divisions as Høeg and Dr. Prasad strengthen their influence at the FDA – and it suggests a greater focus upon rolling back already-approved immunizations at the FDA.

Høeg has often pushed for ending some childhood immunization guidelines in the US in order to be more similar to Denmark, a country with nationalized medicine and a citizenry roughly the size of Wisconsin’s.

In her initial comments, she has kept her attention on vaccination policy – traditionally the purview of Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER) – instead of pharmaceutical oversight.

Doubts Over Qualifications

Høeg has little discernible track record in medication creation, oversight or administrative roles, which has been customary for former heads of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a top consultant to the commissioner and CBER since spring.

“It seems she lacks to have the necessary background” for overseeing the pharmaceutical oversight division, said Dr. Jonathan Howard. “She has not conducted a scientific study. She lacks experience in managing a large organization. She has no expertise in drug approvals.”

Previous commissioners of the center would “grasp regulatory frameworks and the research of drug development”, commented a former acting FDA commissioner. “Clearly, she lacks the sort of resume that previous people who led the center have had.”

This division has an immense portfolio at the FDA, the former commissioner stated.

“The public just zeroes in on the innovative therapies, but the off-patent medication office clears numerous generic medications. There is also a biosimilars division, OTC medication office and other areas, and each of these need to be looked after,” Woodcock noted. “The responsibility you neglect, that is precisely what that I always told people is going to cause problems.”

There is also, a substantial management aspect to the job, which oversees more than 5,000 staff members. “It is a huge administrative position, if you do it right,” Woodcock said.

Official Statement and Disputed Policies

When asked about concerns about Høeg’s qualifications and whether this assignment represents increased cooperation among FDA leaders on immunizations, a press secretary said that the “questions stem from incorrect assumptions”.

“This background is consistent with the responsibilities of her role,” the spokesperson explained, pointing to the months Høeg spent counseling the agency head on “pharmaceutical safety and approval science, including predictive safety algorithms and vaccine surveillance”.

As the temporary head, Dr. Høeg inherits the commissioner’s controversial fast-track approval initiative, a contentious one-day therapy clearance system that allegedly worried her predecessors. “By what process are these therapies being picked for this fast-track system? Who is making the decisions?” Dr. Howard asked. “There’s a lot of secrecy occurring at the regulatory body right now.”

Overall, he said, “the FDA appears to be shifting towards less stringent regulations of most medications, aside from immunizations.”

Documented Past Work on Vaccines

Concerning immunizations, Høeg has a more established, if troubling, track record, some experts have noted. She authored a analysis using unconfirmed crowd-sourced reports to assess the frequency of myocarditis following Covid immunization. She counseled the state of Florida surgeon general Joseph Ladapo, who allegedly have changed statistics to suggest Covid vaccinations are pose a greater threat than they are.

Part of her “policy goals” for the current administration included changing guidelines for recently developed shots and ending “optional” vaccines, she remarked after the election on a podcast. At the FDA, Dr. Høeg has according to sources suggested preventing young men from receiving Covid vaccines.

“She’s an complete ideologue who commences with her beliefs and works backwards to accommodate the science in a highly disingenuous, untruthful fashion,” Dr. Howard argued.

Taking Control and a “Revenge Tour”

Dr. Høeg aligned with other contrarians, {like|